2024-10-16 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**1. Performance Comparison**

Pfizer Inc. (PFE) is a global pharmaceutical company that develops and manufactures medicines and vaccines. 

- **Cumulative Return:** -11.77%
- **S&P 500 (VOO) Cumulative Return:** 135.82%
- **Performance Gap:** -147.59% (This means PFE has underperformed the S&P 500 by 147.59%).
- **Relative Performance:** 0.0 (This indicates that PFE's performance is at the lowest point compared to its historical performance range against the S&P 500).

**2. Recent Price Action**

- **Closing Price:** $29.16
- **5-Day Moving Average:** $29.42
- **20-Day Moving Average:** $29.24
- **60-Day Moving Average:** $29.27

**3. Technical Indicators**

- **RSI:** 48.33 (Neutral)
- **PPO:** 0.15 (Slight bullish signal)
- **Delta_Previous_Relative_Divergence:** -1.74 (Indicates a short-term downward trend)
- **Expected Return:** 0.0% (This indicates that there is no expected return over the next five years compared to the S&P 500).

**4. Recent Earnings and Outlook**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |
| 2023-08-01 | 0.67 | 0.56 |

The most recent earnings for Q2 2024 showed that PFE beat analysts' expectations with EPS of $0.6, exceeding the expected $0.458. This positive performance could be attributed to the strong sales of their flagship products like COVID-19 vaccines and treatments, as well as other blockbuster medications.

**5. News and Recent Issues**

- **Recent Market Outlook:** Pfizer's stock price has been impacted by the declining COVID-19 revenue due to the easing pandemic. However, the company continues to invest in research and development of new drugs and vaccines, hoping to maintain its strong market position.
- **Analyst Opinions:**  Analysts generally hold a "hold" rating on PFE with a mixed outlook for the company. Some analysts are optimistic about the potential of PFE's upcoming drug launches, while others are concerned about the ongoing decline in COVID-19 revenue.
- **Performance Highlights:** While PFE's stock price has underperformed the S&P 500 recently, its strong earnings performance in Q2 2024 could be a sign of a potential turnaround. 

**6. Overall Analysis**

Pfizer Inc. (PFE) has been a reliable and profitable pharmaceutical company for a long time, but its stock performance has been relatively stagnant recently. The decline in COVID-19 related revenue is a primary concern for investors. While PFE has a strong pipeline of potential future drugs, the overall market outlook remains mixed. Investors should monitor the company's upcoming product launches and earnings reports to assess the potential for future growth.

**7. Conclusion**

PFE is a large pharmaceutical company with a diversified portfolio of products. The company faces challenges due to the decline in COVID-19 related revenue, but its strong earnings performance in Q2 2024 suggests potential for a turnaround. Investors should monitor the company's upcoming product launches and earnings reports to assess the potential for future growth. 
